Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qinwei Chen

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Drugs in R&D|October 17, 2023
Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling PathwaysGenhong Li, Jingwei Yao, Zhen Lu, et al.
Gene|December 21, 2022
Stratification and therapeutic potential of ELL in cytogenetic normal acute myeloid leukemiaJie Zha, Mengya Zhong, Guangchao Pan, et al.
Annals of Hematology|September 28, 2025
DGKα inhibition enhances the antitumor effect of chiauranib on transformed follicular lymphomaJiewen Huang, Mengya Zhong, Jingwei Yao, et al.
Quantitative Imaging in Medicine and Surgery|March 31, 2025
Integration of PET/CT parameters and a clinical variable to predict the risk of progression of disease within 24 months (POD24) in follicular lymphomaQiuhui Jiang, Zhijuan Lin, Qinwei Chen, et al.
Translational Oncology|August 19, 2022
Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathwayQiuling Chen, Qian Lai, Yuelong Jiang, et al.
Briefings in Bioinformatics|March 28, 2024
Epigenome-augmented eQTL-hotspots reveal genome-wide transcriptional programs in 36 human tissuesHuanhuan Liu, Qinwei Chen, Jintao Guo, et al.
Experimental Hematology & Oncology|April 17, 2022
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathwaysQinwei Chen, Suqi Deng, Manman Deng, et al.
Leukemia|October 7, 2018
Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemiaBowen Yan, Qinwei Chen, Koji Shimada, et al.
Clinical Epigenetics|October 9, 2019
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repairJing Ye, Jie Zha, Yuanfei Shi, et al.
American Journal of Translational Research|April 12, 2021
Anlotinib suppresses MLL-rearranged acute myeloid leukemia cell growth by inhibiting SETD1A/AKT-mediated DNA damage responseJinzhu Chen, Juan Feng, Zhihong Fang, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Drugs in R&D|October 17, 2023
Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling PathwaysGenhong Li, Jingwei Yao, Zhen Lu, et al.
Gene|December 21, 2022
Stratification and therapeutic potential of ELL in cytogenetic normal acute myeloid leukemiaJie Zha, Mengya Zhong, Guangchao Pan, et al.
Annals of Hematology|September 28, 2025
DGKα inhibition enhances the antitumor effect of chiauranib on transformed follicular lymphomaJiewen Huang, Mengya Zhong, Jingwei Yao, et al.
Quantitative Imaging in Medicine and Surgery|March 31, 2025
Integration of PET/CT parameters and a clinical variable to predict the risk of progression of disease within 24 months (POD24) in follicular lymphomaQiuhui Jiang, Zhijuan Lin, Qinwei Chen, et al.
Translational Oncology|August 19, 2022
Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathwayQiuling Chen, Qian Lai, Yuelong Jiang, et al.
Briefings in Bioinformatics|March 28, 2024
Epigenome-augmented eQTL-hotspots reveal genome-wide transcriptional programs in 36 human tissuesHuanhuan Liu, Qinwei Chen, Jintao Guo, et al.
Experimental Hematology & Oncology|April 17, 2022
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathwaysQinwei Chen, Suqi Deng, Manman Deng, et al.
Leukemia|October 7, 2018
Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemiaBowen Yan, Qinwei Chen, Koji Shimada, et al.
Clinical Epigenetics|October 9, 2019
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repairJing Ye, Jie Zha, Yuanfei Shi, et al.
American Journal of Translational Research|April 12, 2021
Anlotinib suppresses MLL-rearranged acute myeloid leukemia cell growth by inhibiting SETD1A/AKT-mediated DNA damage responseJinzhu Chen, Juan Feng, Zhihong Fang, et al.
Pageof 4